Oncolytic Adenoviruses for Cancer Immunotherapy. Data from Mice, Hamsters, and Humans.

Advances in Cancer Research

Volumn 115, Issue , 2012, Pages 265-318

  Cerullo, Vincenzo ^a,b   Koski, Anniina ^b   Vähä Koskela, Markus ^b   Hemminki, Akseli ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adenovirus; Antigens; Cancer; Immunotherapy

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; CAPSID PROTEIN; CAPSID PROTEIN IX; COMPLEMENT COMPONENT C3; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOPLASMIC RECEPTOR; E1B PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXON PROTEIN; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 6; LONTUCIREV; NEUTRALIZING ANTIBODY; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; ONCOLYTIC ADENOVIRUS; PATTERN RECOGNITION RECEPTOR; PENTON PROTEIN; RANTES; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS;

ACIDIFICATION; ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; ENDOSOME; ENDOTHELIUM CELL; GENE DELETION; GENE EXPRESSION REGULATION; GENE INSERTION; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; INTERNAL RIBOSOME ENTRY SITE; LIFE CYCLE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSGENE; VIRION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; CLINICAL TRIAL (TOPIC); CYTOSOL; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; HAMSTER; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; REVIEW;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; CRICETINAE; CYTOSOL; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSGENES;

EID: 84866784085     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398342-8.00008-2     Document Type: Chapter

References (286)

1. Akbulut H., Zhang L., Tang Y., Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Therapy 2003, 10:388-395.
2. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
3. Alba R., Bosch A., Chillon M. Gutless adenovirus: Last-generation adenovirus for gene therapy. Gene Therapy 2005, 12(Suppl. 1):S18-S27.
4. Alemany R. Cancer selective adenoviruses. Molecular Aspects of Medicine 2007, 28:42-58.
5. Alemany R., Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiology 2009, 4:527-536.
6. Alemany R., Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy 2001, 8:1347-1353.
7. Andoniou C.E., van Dommelen S.L., Voigt V., Andrews D.M., Brizard G., Asselin-Paturel C., et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nature Immunology 2005, 6:1011-1019.
8. Andrews D.M., Andoniou C.E., Scalzo A.A., van Dommelen S.L., Wallace M.E., Smyth M.J., et al. Cross-talk between dendritic cells and natural killer cells in viral infection. Molecular Immunology 2005, 42:547-555.
9. Appledorn D.M., Kiang A., McBride A., Jiang H., Seregin S., Scott J.M., et al. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Therapy 2008, 15:885-901.
10. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology 1999, 17:2105-2116.
11. Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nature Reviews. Immunology 2010, 10:787-796.
12. Bauerschmitz G.J., Guse K., Kanerva A., Menzel A., Herrmann I., Desmond R.A., et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Molecular Therapy 2006, 14:164-174.
13. Bauerschmitz G.J., Nettelbeck D.M., Kanerva A., Baker A.H., Hemminki A., Reynolds P.N., et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Research 2002, 62:1271-1274.
14. Bayo-Puxan N., Cascallo M., Gros A., Huch M., Fillat C., Alemany R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. The Journal of General Virology 2006, 87:2487-2495.
15. Beatty G.L., Paterson Y. Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunologic Research 2001, 24:201-210.
16. Berk A.J. (2007). Adenoviridae: the viruses and their replication. In: B. N. Fields, D. M. Knipe, P. M. Howley (Eds.), Fields Virology. fifth ed. (pp. 2355-2394). Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia.
17. Berruti A., Pia A., Terzolo M. Advances in pancreatic neuroendocrine tumor treatment. The New England Journal of Medicine 2011, 364:1871-1872. author reply 1873-1874.
18. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
19. Boniface K., Blom B., Liu Y.J., de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: Human T-helper cell differentiation revisited. Immunological Reviews 2008, 226:132-146.
20. Bortolanza S., Bunuales M., Otano I., Gonzalez-Aseguinolaza G., Ortiz-de-Solorzano C., Perez D., et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Molecular Therapy 2009, 17:614-622.
21. Bottini A., Generali D., Brizzi M.P., Fox S.B., Bersiga A., Bonardi S., et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Journal of Clinical Oncology 2006, 24:3623-3628.
22. Bowen G.P., Borgland S.L., Lam M., Libermann T.A., Wong N.C., Muruve D.A. Adenovirus vector-induced inflammation: Capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Human Gene Therapy 2002, 13:367-379.
23. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
24. Brunetti-Pierri N., Ng P. Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Current Gene Therapy 2009, 9:329-340.
25. Brunetti-Pierri N., Ng P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Human Molecular Genetics 2011, 20:R7-R13.
26. Brunetti-Pierri N., Ng T., Iannitti D.A., Palmer D.J., Beaudet A.L., Finegold M.J., et al. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Human Gene Therapy 2006, 17:391-404.
27. Brunetti-Pierri N., Palmer D.J., Beaudet A.L., Carey K.D., Finegold M., Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Human Gene Therapy 2004, 15:35-46.
28. Campos S.K., Barry M.A. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006, 349:453-462.
29. Campos S.K., Barry M.A. Current advances and future challenges in adenoviral vector biology and targeting. Current Gene Therapy 2007, 7:189-204.
30. Carlisle R.C., Di Y., Cerny A.M., Sonnen A.F., Sim R.B., Green N.K., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009, 113:1909-1918.
31. Cerullo V., Diaconu I., Kangasniemi L., Rajecki M., Escutenaire S., Koski A., et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Molecular Therapy 2011, 19:1737-1746.
32. Cerullo V., Pesonen S., Diaconu I., Escutenaire S., Arstila P.T., Ugolini M., et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Research 2010, 70:4297-4309.
33. Cerullo V., Seiler M.P., Mane V., Brunetti-Pierri N., Clarke C., Bertin T.K., et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Molecular Therapy 2007, 15:378-385.
34. Chang C.J., Chen Y.H., Huang K.W., Cheng H.W., Chan S.F., Tai K.F., et al. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007, 45:746-754.
35. Chang J., Zhao X., Wu X., Guo Y., Guo H., Cao J., et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biology & Therapy 2009, 8:676-682.
36. Chen X., Lin X., Zhao J., Shi W., Zhang H., Wang Y., et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Molecular Therapy 2008, 16:749-756.
37. Chen J., Wang J., Li J., Wu Q., Chu Lim F., Yang P., et al. Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession. Molecular Therapy 2008, 16:1500-1506.
38. Chiocca E.A., Smith K.M., McKinney B., Palmer C.A., Rosenfeld S., Lillehei K., et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Molecular Therapy 2008, 16:618-626.
39. Cody J.J., Douglas J.T. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Therapy 2009, 16:473-488.
40. Coley W.B. II. Contribution to the knowledge of sarcoma. Annals of Surgery 1891, 14:199-220.
41. Correale P., Botta C., Cusi M., Del Vecchio M., De Santi M., Gori Savellini G., et al. Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. International Journal of Cancer 2012, 130:1577-1589.
42. Coyne C.B., Bergelson J.M. CAR: a virus receptor within the tight junction. Advanced Drug Delivery Reviews 2005, 57:869-882.
43. Critchley-Thorne R.J., Simons D.L., Yan N., Miyahira A.K., Dirbas F.M., Johnson D.L., et al. Impaired interferon signaling is a common immune defect in human cancer. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:9010-9015.
44. Croyle M.A., Le H.T., Linse K.D., Cerullo V., Toietta G., Beaudet A.L., et al. PEGylated helper-dependent adenoviral vectors: Highly efficient vectors with an enhanced safety profile. Gene Therapy 2005, 12:579-587.
45. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
46. Danthinne X., Imperiale M.J. Production of first generation adenovirus vectors: A review. Gene Therapy 2000, 7:1707-1714.
47. Degli-Esposti M.A., Smyth M.J. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nature Reviews. Immunology 2005, 5:112-124.
48. Dhar D., Toth K., Wold W.S. Syrian hamster tumor model to study oncolytic Ad5-based vectors. Methods in Molecular Biology 2012, 797:53-63.
49. Diaconu I., Cerullo V., Escutenaire S., Kanerva A., Bauerschmitz G.J., Hernandez-Alcoceba R., et al. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. The Journal of Gene Medicine 2010, 12:435-445.
50. Dias J.D., Hemminki O., Diaconu I., Hirvinen M., Bonetti A., Guse K., et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Therapy, 2011, Nov 10, 1-11. doi: 10.1038/gt.2011.176.
51. Diaz R.M., Galivo F., Kottke T., Wongthida P., Qiao J., Thompson J., et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Research 2007, 67:2840-2848.
52. DiPaolo N., Ni S., Gaggar A., Strauss R., Tuve S., Li Z.Y., et al. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Molecular Therapy 2006, 13:756-765.
53. Dmitriev I.P., Kashentseva E.A., Curiel D.T. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. Journal of Virology 2002, 76:6893-6899.
54. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology 1998, 72:9706-9713.
55. Dranoff G. GM-CSF-based cancer vaccines. Immunological Reviews 2002, 188:147-154.
56. Edelman J., Nemunaitis J. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Current Opinion in Molecular Therapeutics 2003, 5:611-617.
57. Edukulla R., Woller N., Mundt B., Knocke S., Gurlevik E., Saborowski M., et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Research 2009, 69:1448-1458.
58. Eriksson M., Guse K., Bauerschmitz G., Virkkunen P., Tarkkanen M., Tanner M., et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Molecular Therapy 2007, 15:2088-2093.
59. Franchi L., Park J.H., Shaw M.H., Marina-Garcia N., Chen G., Kim Y.G., et al. Intracellular NOD-like receptors in innate immunity, infection and disease. Cellular Microbiology 2008, 10:1-8.
60. Freytag S.O., Rogulski K.R., Paielli D.L., Gilbert J.D., Kim J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Human Gene Therapy 1998, 9:1323-1333.
61. Fritz J.H., Ferrero R.L., Philpott D.J., Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nature Immunology 2006, 7:1250-1257.
62. Fueyo J., Gomez-Manzano C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19:2-12.
63. Gabaglia C.R., DeLaney A., Gee J., Halder R., Graham F.L., Gauldie J., et al. Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. Journal of Translational Medicine 2010, 8:98.
64. Gabaglia C.R., Sercarz E.E., Diaz-De-Durana Y., Hitt M., Graham F.L., Gauldie J., et al. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes. Vaccine 2004, 23:247-257.
65. Galanis E., Okuno S., Nascimento A., Lewis B., Lee R., Oliveira A., et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy 2005, 12:437-445.
66. Ganesan L.P., Mohanty S., Kim J., Clark K.R., Robinson J.M., Anderson C.L. Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathogens 2011, 7:e1002281.
67. Gao J.Q., Kanagawa N., Xu D.H., Han M., Sugita T., Hatanaka Y., et al. Combination of two fiber-mutant adenovirus vectors, one encoding the chemokine FKN and another encoding cytokine interleukin 12, elicits notably enhanced anti-tumor responses. Cancer Immunology, Immunotherapy 2008, 57:1657-1664.
68. Gao J.Q., Sugita T., Kanagawa N., Iida K., Eto Y., Motomura Y., et al. A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma. Biochemical and Biophysical Research Communications 2005, 328:1043-1050.
69. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. Journal of the National Cancer Institute 2006, 98:298-300.
70. Glasgow J.N., Kremer E.J., Hemminki A., Siegal G.P., Douglas J.T., Curiel D.T. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology 2004, 324:103-116.
71. Gordon Y.J., Romanowski E., Araullo-Cruz T. An ocular model of adenovirus type 5 infection in the NZ rabbit. Investigative Ophthalmology & Visual Science 1992, 33:574-580.
72. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annual Review of Immunology 2005, 23:515-548.
73. Guse K., Diaconu I., Rajecki M., Sloniecka M., Hakkarainen T., Ristimaki A., et al. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Therapy 2009, 16:1009-1020.
74. Guse K., Ranki T., Ala-Opas M., Bono P., Sarkioja M., Rajecki M., et al. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Molecular Cancer Therapeutics 2007, 6:2728-2736.
75. Hakkarainen T., Rajecki M., Sarparanta M., Tenhunen M., Airaksinen A.J., Desmond R.A., et al. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clinical Cancer Research 2009, 15:5396-5403.
76. Hall S.J., Canfield S.E., Yan Y., Hassen W., Selleck W.A., Chen S.H. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Therapy 2002, 9:511-517.
77. Hallden G., Hill R., Wang Y., Anand A., Liu T.C., Lemoine N.R., et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Molecular Therapy 2003, 8:412-424.
78. Han Z., Hong Z., Gao Q., Chen C., Hao Z., Ji T., et al. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Human Gene Therapy 2011, 23:32-45.
79. Hartman Z.C., Osada T., Glass O., Yang X.Y., Lei G.J., Lyerly H.K., et al. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Research 2010, 70:7209-7220.
80. Hegenbarth S., Gerolami R., Protzer U., Tran P.L., Brechot C., Gerken G., et al. Liver sinusoidal endothelial cells are not permissive for adenovirus type 5. Human Gene Therapy 2000, 11:481-486.
81. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Medicine 2000, 6:1134-1139.
82. Hemminki O., Bauerschmitz G., Hemmi S., Lavilla-Alonso S., Diaconu I., Guse K., et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Therapy 2011, 18:288-296.
83. Hemminki O., Diaconu I., Hemmi S., Kanerva A., Cerullo V., Escutenaire S., et al. Human data with a desmoglein 2 binding oncolytic adenovirus Ad3-hTERT-E1A. Human Gene Therapy 2011, 22:A28-A29.
84. Hierholzer J.C. Adenoviruses in the immunocompromised host. Clinical Microbiology Reviews 1992, 5:262-274.
85. Higginbotham J.N., Seth P., Blaese R.M., Ramsey W.J. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Human Gene Therapy 2002, 13:129-141.
86. Hjorth R.N., Bonde G.M., Pierzchala W.A., Vernon S.K., Wiener F.P., Levner M.H., et al. A new hamster model for adenoviral vaccination. Archives of Virology 1988, 100:279-283.
87. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363:711-723.
88. Hoffmann J.A. The immune response of Drosophila. Nature 2003, 426:33-38.
89. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
90. Huber C.H., Wolfel T. Immunotherapy of cancer: From vision to standard clinical practice. Journal of Cancer Research and Clinical Oncology 2004, 130:367-374.
91. Hwang K.S., Cho W.K., Yoo J., Yun H.J., Kim S., Im D.S. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer 2005, 5:51.
92. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine & Growth Factor Reviews 2002, 13:95-109.
93. Imperiale M.J., Enquist L.W. What's in a Name?. Journal of Virology 2011, 85:5245.
94. Inohara C., McDonald C., Nunez G. NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease. Annual Review of Biochemistry 2005, 74:355-383.
95. Iqbal Ahmed C.M., Johnson D.E., Demers G.W., Engler H., Howe J.A., Wills K.N., et al. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Therapy 2001, 8:788-795.
96. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
97. Jiang H., Alonso M.M., Gomez-Manzano C., Piao Y., Fueyo J. Oncolytic viruses and DNA-repair machinery: Overcoming chemoresistance of gliomas. Expert Review of Anticancer Therapy 2006, 6:1585-1592.
98. Jiang H., Wang Z., Serra D., Frank M.M., Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Molecular Therapy 2004, 10:1140-1142.
99. Jiang H., White E.J., Rios-Vicil C.I., Xu J., Gomez-Manzano C., Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. Journal of Virology 2011, 85:4720-4729.
100. Jin H.S., Park E.K., Lee J.M., NamKoong S.E., Kim D.G., Lee Y.J., et al. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecologic Oncology 2005, 97:559-567.
101. Jin H.T., Youn J.I., Kim H.J., Lee J.B., Ha S.J., Koh J.S., et al. Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Human Gene Therapy 2005, 16:328-338.
102. Kalu S.U., Loeffelholz M., Beck E., Patel J.A., Revai K., Fan J., et al. Persistence of adenovirus nucleic acids in nasopharyngeal secretions: A diagnostic conundrum. The Pediatric Infectious Disease Journal 2010, 29:746-750.
103. Kanagawa N., Gao J.Q., Motomura Y., Yanagawa T., Mukai Y., Yoshioka Y., et al. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor. Biochemical and Biophysical Research Communications 2008, 372:821-825.
104. Kanerva A., Bauerschmitz G.J., Yamamoto M., Lam J.T., Alvarez R.D., Siegal G.P., et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Therapy 2004, 11:552-559.
105. Kanerva A., Hemminki A. Modified adenoviruses for cancer gene therapy. International Journal of Cancer 2004, 110:475-480.
106. Kanerva A., Mikheeva G.V., Krasnykh V., Coolidge C.J., Lam J.T., Mahasreshti P.J., et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clinical Cancer Research 2002, 8:275-280.
107. Kanerva A., Zinn K.R., Chaudhuri T.R., Lam J.T., Suzuki K., Uil T.G., et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Molecular Therapy 2003, 8:449-458.
108. Kangasniemi L., Kiviluoto T., Kanerva A., Raki M., Ranki T., Sarkioja M., et al. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clinical Cancer Research 2006, 12:3137-3144.
109. Kanneganti T.D., Lamkanfi M., Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007, 27:549-559.
110. Kaur B., Cripe T.P., Chiocca E.A. " Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Current Gene Therapy 2009, 9:341-355.
111. Kawai T., Akira S. TLR signaling. Cell Death and Differentiation 2006, 13:816-825.
112. Khare R., Chen C.Y., Weaver E.A., Barry M.A. Advances and future challenges in adenoviral vector pharmacology and targeting. Current Gene Therapy 2011, 11:241-258.
113. Khare R., May S.M., Vetrini F., Weaver E.A., Palmer D., Rosewell A., et al. Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Molecular Therapy: The Journal of the American Society of Gene Therapy 2011, 19:1254-1262.
114. Kim J., Lee B., Kim J.S., Yun C.O., Kim J.H., Lee Y.J., et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Letters 2002, 180:23-32.
115. Kirkwood J.M., Ernstoff M.S., Davis C.A., Reiss M., Ferraresi R., Rudnick S.A. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Annals of Internal Medicine 1985, 103:32-36.
116. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?. Gene Therapy 2001, 8:89-98.
117. Koski A., Kangasniemi L., Escutenaire S., Pesonen S., Cerullo V., Diaconu I., et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Molecular Therapy 2010, 18:1874-1884.
118. Krasnykh V.N., Mikheeva G.V., Douglas J.T., Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. Journal of Virology 1996, 70:6839-6846.
119. Kretschmer P.J., Jin F., Chartier C., Hermiston T.W. Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus. Molecular Therapy 2005, 12:118-127.
120. Kurachi S., Koizumi N., Sakurai F., Kawabata K., Sakurai H., Nakagawa S., et al. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Therapy 2007, 14:266-274.
121. Law L.K., Davidson B.L. What does it take to bind CAR?. Molecular Therapy 2005, 12:599-609.
122. Lee W.P., Wen Y., Varnum B., Hung M.C. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 2002, 21:329-336.
123. Lei N., Shen F.B., Chang J.H., Wang L., Li H., Yang C., et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Therapy 2009, 16:33-43.
124. Leppard K.N. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. The Journal of General Virology 1997, 78(Pt 9):2131-2138.
125. Li Y., Chen Y., Dilley J., Arroyo T., Ko D., Working P., et al. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Molecular Cancer Therapeutics 2003, 2:1003-1009.
126. Li J.-L., Liu H.-L., Zhang X.-R., Xu J.-P., Hu W.-K., Liang M., et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Therapy 2009, 16:376-382.
127. Lichtenstein D.L., Toth K., Doronin K., Tollefson A.E., Wold W.S. Functions and mechanisms of action of the adenovirus E3 proteins. International Reviews of Immunology 2004, 23:75-111.
128. Lieber A., He C.Y., Meuse L., Schowalter D., Kirillova I., Winther B., et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of Virology 1997, 71:8798-8807.
129. Linardakis E., Bateman A., Phan V., Ahmed A., Gough M., Olivier K., et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Research 2002, 62:5495-5504.
130. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annual Review of Immunology 2005, 23:275-306.
131. Liu Y., Ehtesham M., Samoto K., Wheeler C.J., Thompson R.C., Villarreal L.P., et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Therapy 2002, 9:9-15.
132. Liu Y., Tuve S., Persson J., Beyer I., Yumul R., Li Z.Y., et al. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Therapy 2011, 18:407-418.
133. Liu Q., Zaiss A.K., Colarusso P., Patel K., Haljan G., Wickham T.J., et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Human Gene Therapy 2003, 14:627-643.
134. Liu Y., Zhang X., Zhang W., Chen Z., Chan T., Ali K., et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Therapy 2002, 9:202-208.
135. Lladser A., Mougiakakos D., Tufvesson H., Ligtenberg M.A., Quest A.F., Kiessling R., et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Molecular Therapy 2011, 19:594-601.
136. Lladser A., Sanhueza C., Kiessling R., Quest A.F. Is survivin the potential Achilles' heel of cancer?. Advances in Cancer Research 2011, 111:1-37.
137. Lohr F., Hu K., Haroon Z., Samulski T.V., Huang Q., Beaty J., et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Molecular Therapy 2000, 2:195-203.
138. Lukacher A.E. IFN-gamma suspends the killing license of anti-tumor CTLs. The Journal of Clinical Investigation 2002, 110:1407-1409.
139. Lupu C.M., Eisenbach C., Lupu A.D., Kuefner M.A., Hoyler B., Stremmel W., et al. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncology Reports 2007, 18:745-748.
140. Lyons A., Longfield J., Kuschner R., Straight T., Binn L., Seriwatana J., et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008, 26:2890-2898.
141. Lyons M., Onion D., Green N.K., Aslan K., Rajaratnam R., Bazan-Peregrino M., et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Molecular Therapy 2006, 14:118-128.
142. Maheshwari R.K., Banerjee D.K., Waechter C.J., Olden K., Friedman R.M. Interferon treatment inhibits glycosylation of a viral protein. Nature 1980, 287:454-456.
143. Maheshwari R.K., Husain M.M., Attallah A.M., Friedman R.M. Tunicamycin treatment inhibits the antiviral activity of interferon in mice. Infection and Immunity 1983, 41:61-66.
144. Manickan E., Smith J.S., Tian J., Eggerman T.L., Lozier J.N., Muller J., et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Molecular Therapy 2006, 13:108-117.
145. Mantwill K., Kohler-Vargas N., Bernshausen A., Bieler A., Lage H., Kaszubiak A., et al. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Research 2006, 66:7195-7202.
146. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28:950-957.
147. Mazumder A., Rosenberg S.A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. The Journal of Experimental Medicine 1984, 159:495-507.
148. McLoughlin J.M., McCarty T.M., Cunningham C., Clark V., Senzer N., Nemunaitis J., et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Annals of Surgical Oncology 2005, 12:825-830.
149. Mizuguchi H., Koizumi N., Hosono T., Ishii-Watabe A., Uchida E., Utoguchi N., et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Therapy 2002, 9:769-776.
150. Mond J.J., Brunswick M. A role for IFN-gamma and NK cells in immune responses to T cell-regulated antigens types 1 and 2. Immunological Reviews 1987, 99:105-118.
151. Mundt A.J., Vijayakumar S., Nemunaitis J., Sandler A., Schwartz H., Hanna N., et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clinical Cancer Research 2004, 10:5747-5753.
152. Muruve D.A., Barnes M.J., Stillman I.E., Libermann T.A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Human Gene Therapy 1999, 10:965-976.
153. Muruve D.A., Pétrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452:103-107.
154. Nakamura T., Sato K., Hamada H. Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. Journal of Virology 2003, 77:2512-2521.
155. Narumi K., Kondoh A., Udagawa T., Hara H., Goto N., Ikarashi Y., et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Science 2010, 101:1686-1694.
156. Nasu Y., Ebara S., Kumon H. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer. Nippon Rinsho 2004, 62:1181-1191.
157. Nayak S., Herzog R.W. Progress and prospects: Immune responses to viral vectors. Gene Therapy 2010, 17:295-304.
158. Nemunaitis J., Cunningham C., Tong A.W., Post L., Netto G., Paulson A.S., et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Therapy 2003, 10:341-352.
159. Nemunaitis J., Ganly I., Khuri F., Arseneau J., Kuhn J., McCarty T., et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Research 2000, 60:6359-6366.
160. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. Journal of Clinical Oncology 2001, 19:289-298.
161. Nemunaitis J., Meyers T., Senzer N., Cunningham C., West H., Vallieres E., et al. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Molecular Therapy 2006, 13:1185-1191.
162. Nemunaitis J., Senzer N., Cunningham C., Dubensky T.W. Virus-mediated killing of cells that lack p53 activity. Drug Resistance Updates 2001, 4:289-291.
163. Nemunaitis J., Senzer N., Sarmiento S., Zhang Y.A., Arzaga R., Sands B., et al. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Therapy 2007, 14:885-893.
164. Nemunaitis J., Tong A., Nemunaitis M., Senzer N., Phadke A.P., Chen S., et al. Phase I study of intratumoral injection with telomerase specific replication competent oncolytic adenovirus, telomelysin (OBP-301) in advanced cancer. Molecular Therapy 2009, 17:S283.
165. Nemunaitis J., Vorhies J.S., Pappen B., Senzer N. 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Therapy 2007, 14:762-763.
166. Nociari M., Ocheretina O., Schoggins J.W., Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. Journal of Virology 2007, 81:4145-4157.
167. Nokisalmi P., Pesonen S., Escutenaire S., Sarkioja M., Raki M., Cerullo V., et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clinical Cancer Research 2010, 16:3035-3043.
168. Nowak A.K., Lake R.A., Marzo A.L., Scott B., Heath W.R., Collins E.J., et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. Journal of Immunology 2003, 170:4905-4913.
169. Nunes F.A., Furth E.E., Wilson J.M., Raper S.E. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Human Gene Therapy 1999, 10:2515-2526.
170. Odaka M., Sterman D.H., Wiewrodt R., Zhang Y., Kiefer M., Amin K.M., et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Research 2001, 61:6201-6212.
171. Odaka M., Wiewrodt R., DeLong P., Tanaka T., Zhang Y., Kaiser L., et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Molecular Therapy 2002, 6:210-218.
172. Ohashi M., Yoshida K., Kushida M., Miura Y., Ohnami S., Ikarashi Y., et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. British Journal of Cancer 2005, 93:441-449.
173. O'Neill L.A. When signaling pathways collide: Positive and negative regulation of toll-like receptor signal transduction. Immunity 2008, 29:12-20.
174. Ono H.A., Davydova J.G., Adachi Y., Takayama K., Barker S.D., Reynolds P.N., et al. Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. Journal of Gastroenterology 2005, 40:31-42.
175. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
176. Orend G., Linkwitz A., Doerfler W. Selective sites of adenovirus (foreign) DNA integration into the hamster genome: Changes in integration patterns. Journal of Virology 1994, 68:187-194.
177. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6:611-623.
178. Othman M., Labelle A., Mazzetti I., Elbatarny H.S., Lillicrap D. Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007, 109:2832-2839.
179. Pacini D.L., Dubovi E.J., Clyde W.A. A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis 1984, 150:92-97.
180. Park E.K., Bae S.M., Kwak S.Y., Lee S.J., Kim Y.W., Han C.H. Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model. Immunology 2008, 124:461-468.
181. Park M.Y., Kim D.R., Jung H.W., Yoon H.I., Lee J.H., Lee C.T. Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta. Cancer Gene Therapy 2010, 17:356-364.
182. Pesonen S., Cerullo V., Escutenaire S., Raki M., Kangasniemi L., Nokisalmi P., et al. Treatment of patients with advanced and refractory solid tumors with oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF. Molecular Therapy 2010, 18:1874-1884.
183. Pesonen S., Diaconu I., Cerullo V., Escutenaire S., Raki M., Kangasniemi L., et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. International Journal of Cancer 2011, 130:1937-1947.
184. Pesonen S., Diaconu I., Cerullo V., Ranki T., Kangasniemi L., Escutenaire S., et al. Chimeric oncolytic adenovirus Ad5/3-hTERT-E1A-CD40L for the treatment of advanced solid tumors: Preclinical and clinical evaluation. Human Gene Therapy 2011, 22:A120-A.
185. Pesonen S., Nokisalmi P., Escutenaire S., Sarkioja M., Raki M., Cerullo V. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Therapy 2010, 17:892-904.
186. Petrilli V., Dostert C., Muruve D.A., Tschopp J. The inflammasome: A danger sensing complex triggering innate immunity. Current Opinion in Immunology 2007, 19:615-622.
187. Prestwich R.J., Harrington K.J., Pandha H.S., Vile R.G., Melcher A.A., Errington F. Oncolytic viruses: A novel form of immunotherapy. Expert Review of Anticancer Therapy 2008, 8:1581-1588.
188. Prestwich R.J., Harrington K.J., Vile R.G., Melcher A.A. Immunotherapeutic potential of oncolytic virotherapy. The Lancet Oncology 2008, 9:610-612.
189. Prieto J., Qian C., Sangro B., Melero I., Mazzolini G. Biologic therapy of liver tumors. The Surgical Clinics of North America 2004, 84:673-696.
190. Qi X., Chang Z., Song J., Gao G., Shen Z. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anti-Cancer Drugs 2011, 22:556-562.
191. Qin X.Q., Beckham C., Brown J.L., Lukashev M., Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Molecular Therapy 2001, 4:356-364.
192. Raja Gabaglia C., Diaz de Durana Y., Graham F.L., Gauldie J., Sercarz E.E., Braciak T.A. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Research 2007, 67:2290-2297.
193. Rajecki M., af Hallstrom T., Hakkarainen T., Nokisalmi P., Hautaniemi S., Nieminen A.I., et al. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. International Journal of Cancer 2009, 125:2441-2449.
194. Rajecki M., Kanerva A., Stenman U.H., Tenhunen M., Kangasniemi L., Sarkioja M. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Molecular Cancer Therapeutics 2007, 6:742-751.
195. Ramesh N., Ge Y., Ennist D.L., Zhu M., Mina M., Ganesh S., et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clinical Cancer Research 2006, 12:305-313.
196. Ranki T., Sarkioja M., Hakkarainen T., von Smitten K., Kanerva A., Hemminki A. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. International Journal of Cancer 2007, 121:165-174.
197. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.-P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 2003, 80:148-158.
198. Reay J., Kim S.H., Lockhart E., Kolls J., Robbins P.D. Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response. Cancer Gene Therapy 2009, 16:776-785.
199. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Research 2002, 62:6070-6079.
200. Rivera A.A., Wang M., Suzuki K., Uil T.G., Krasnykh V., Curiel D.T., et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004, 320:121-134.
201. Robinson M., Ge Y., Ko D., Yendluri S., Laflamme G., Hawkins L., et al. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression. Cancer Gene Therapy 2008, 15:9-17.
202. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 1997, 57:2559-2563.
203. Rodriguez-Rocha H., Gomez-Gutierrez J.G., Garcia-Garcia A., Rao X.M., Chen L., McMasters K.M., et al. Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 2011, 416:9-15.
204. Rojas J.J., Guedan S., Searle P.F., Martinez-Quintanilla J., Gil-Hoyos R., Alcayaga-Miranda F., et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Molecular Therapy 2010, 18:1960-1971.
205. Rowan K. Oncolytic viruses move forward in clinical trials. Journal of the National Cancer Institute 2010, 102:590-595.
206. Rowe W.P., Huebner R.J., Gilmore L.K., Parrott R.H., Ward T.G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proceedings of the Society for Experimental Biology and Medicine 1953, 84:570-573.
207. Russell W.C. Update on adenovirus and its vectors. The Journal of General Virology 2000, 81:2573-2604.
208. Rux J.J., Burnett R.M. Adenovirus structure. Human Gene Therapy 2004, 15:1167-1176.
209. Sandberg L., Papareddy P., Silver J., Bergh A., Mei Y.F. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells. Human Gene Therapy 2009, 20:361-373.
210. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. Journal of Clinical Oncology 2004, 22:1389-1397.
211. Santodonato L., Ferrantini M., Palombo F., Aurisicchio L., Delmastro P., La Monica N., et al. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Therapy 2001, 8:63-72.
212. Sari Pesonen I.D., Cerullo V., Ranki T., Kangasniemi L., Escutenaire S., Kanerva A., et al. Chimeric oncolytic adenovirus Ad5/3-hTERT-CD40L for the treatment of advanced solid tumors: Assessment of safety and immunological responses in patients 2011, 84. Mayo Clinic, Las Vegas, NV.
213. Sarkar D., Lebedeva I.V., Su Z.Z., Park E.S., Chatman L., Vozhilla N., et al. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Research 2007, 67:5434-5442.
214. Sarkar D., Su Z.Z., Fisher P.B. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Efficacious reagents for cancer gene therapy. Cell Cycle 2006, 5:1531-1536.
215. Sarkar D., Su Z.Z., Park E.S., Vozhilla N., Dent P., Curiel D.T., et al. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Therapy 2008, 15:293-302.
216. Sarkar D., Su Z.Z., Vozhilla N., Park E.S., Gupta P., Fisher P.B. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:14034-14039.
217. Sarkar D., Su Z.Z., Vozhilla N., Park E.S., Randolph A., Valerie K., et al. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Research 2005, 65:9056-9063.
218. Satoh T., Saika T., Ebara S., Kusaka N., Timme T.L., Yang G., et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Research 2003, 63:7853-7860.
219. Schuster M., Nechansky A., Kircheis R. Cancer immunotherapy. Biotechnology Journal 2006, 1:138-147.
220. Seiler M.P., Cerullo V., Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: Challenges and prospects. Current Gene Therapy 2007, 7:297-305.
221. Seiler M.P., Gottschalk S., Cerullo V., Ratnayake M., Mane V.P., Clarke C., et al. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Molecular Therapy 2007, 15:386-392.
222. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research 2004, 64:6337-6343.
223. Seregin S.S., Aldhamen Y.A., Appledorn D.M., Hartman Z.C., Schuldt N.J., Scott J., et al. Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 2010, 116:1669-1677.
224. Shaw M.H., Reimer T., Kim Y.G., Nunez G. NOD-like receptors (NLRs): Bona fide intracellular microbial sensors. Current Opinion in Immunology 2008, 20:377-382.
225. Shayakhmetov D.M., Gaggar A., Ni S., Li Z.Y., Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. Journal of Virology 2005, 79:7478-7491.
226. Shenoy A.R., Kim B.H., Choi H.P., Matsuzawa T., Tiwari S., MacMicking J.D. Emerging themes in IFN-gamma-induced macrophage immunity by the p47 and p65 GTPase families. Immunobiology 2007, 212:771-784.
227. Shimamura M., Morishita R. Naked plasmid DNA for gene therapy. Current Gene Therapy 2011, 11:433.
228. Smith T.A., Idamakanti N., Rollence M.L., Marshall-Neff J., Kim J., Mulgrew K., et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Human Gene Therapy 2003, 14:777-787.
229. Sorensen M.R., Holst P.J., Steffensen M.A., Christensen J.P., Thomsen A.R. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010, 28:6757-6764.
230. Spencer J.F., Sagartz J.E., Wold W.S., Toth K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Therapy 2009, 16:912-922.
231. Sterman D.H., Gillespie C.T., Carroll R.G., Coughlin C.M., Lord E.M., Sun J., et al. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Practice. Oncology 2006, 3:633-639.
232. Sterman D.H., Recio A., Carroll R.G., Gillespie C.T., Haas A., Vachani A., et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clinical Cancer Research 2007, 13:4456-4466.
233. Sterman D.H., Recio A., Haas A.R., Vachani A., Katz S.I., Gillespie C.T., et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Molecular Therapy 2010, 18:852-860.
234. Stone D., Liu Y., Shayakhmetov D., Li Z.Y., Ni S., Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. Journal of Virology 2007, 81:4866-4871.
235. Sun M., Richards S., Prasad D.V., Mai X.M., Rudensky A., Dong C. Characterization of mouse and human B7-H3 genes. Journal of Immunology 2002, 168:6294-6297.
236. Suzuki M., Cela R., Bertin T.K., Sule G., Cerullo V., Rodgers J.R., et al. NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. Human Gene Therapy 2011, 22:1071-1082.
237. Suzuki M., Cerullo V., Bertin T., Cela R., Clarke C., Guenther M., et al. MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to Helper-dependent adenovirus. Human Gene Therapy 2009, 21:325-336.
238. Suzuki M., Cerullo V., Bertin T.K., Cela R., Clarke C., Guenther M., et al. MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus. Human Gene Therapy 2010, 21:325-336.
239. Thomas D.L., Fraser N.W. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Molecular Therapy 2003, 8:543-551.
240. Thomas M.A., Spencer J.F., La Regina M.C., Dhar D., Tollefson A.E., Toth K., et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Research 2006, 66:1270-1276.
241. Tollefson A.E., Scaria A., Hermiston T.W., Ryerse J.S., Wold L.J., Wold W.S. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. Journal of Virology 1996, 70:2296-2306.
242. Tong A.W., Nemunaitis J., Su D., Zhang Y., Cunningham C., Senzer N., et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients. Molecular Therapy 2005, 11:160-172.
243. Toth K., Spencer J.F., Tollefson A.E., Kuppuswamy M., Doronin K., Lichtenstein D.L., et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Human Gene Therapy 2005, 16:139-146.
244. Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. The Journal of Experimental Medicine 1992, 176:1453-1457.
245. Trinchieri G., Aden D.P., Knowles B.B. Cell-mediated cytotoxicity to SV40-specific tumour-associated antigens. Nature 1976, 261:312-314.
246. Tsai V., Varghese R., Ravindran S., Ralston R., Vellekamp G. Complement component C1q and anti-hexon antibody mediate adenovirus infection of a CAR-negative cell line. Viral Immunology 2008, 21:469-476.
247. Tuve S., Liu Y., Tragoolpua K., Jacobs J.D., Yumul R.C., Li Z.Y., et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009, 27:4225-4239.
248. Tuve S., Wang H., Ware C., Liu Y., Gaggar A., Bernt K. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. Journal of Virology 2006, 80:12109-12120.
249. Vaha-Koskela M.J., Heikkila J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Letters 2007, 254:178-216.
250. van Beusechem V.W., van den Doel P.B., Grill J., Pinedo H.M., Gerritsen W.R. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Research 2002, 62:6165-6171.
251. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
252. VanOosten R.L., Griffith T.S. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Research 2007, 67:11980-11990.
253. Veltrop-Duits L.A., van Vreeswijk T., Heemskerk B., Thijssen J.C., El Seady R., Jol-van der Zijde E.M., et al. High titers of pre-existing adenovirus serotype-specific neutralizing antibodies in the host predict viral reactivation after allogeneic stem cell transplantation in children. Clinical Infectious Diseases 2011, 52:1405-1413.
254. Vigne E., Mahfouz I., Dedieu J.F., Brie A., Perricaudet M., Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. Journal of Virology 1999, 73:5156-5161.
255. Volk A.L., Rivera A.A., Kanerva A., Bauerschmitz G., Dmitriev I., Nettelbeck D.M., et al. Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biology & Therapy 2003, 2:511-515.
256. Volpers C., Kochanek S. Adenoviral vectors for gene transfer and therapy. The Journal of Gene Medicine 2004, 6(Suppl. 1):S164-S171.
257. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
258. Wang K., Huang S., Kapoor-Munshi A., Nemerow G. Adenovirus internalization and infection require dynamin. Journal of Virology 1998, 72:3455-3458.
259. Wang E., Panelli M., Marincola F.M. Autologous tumor rejection in humans: Trimming the myths. Immunological Investigations 2006, 35:437-458.
260. Wang E., Selleri S., Sabatino M., Monaco A., Pos Z., Worschech A., et al. Spontaneous and treatment-induced cancer rejection in humans. Expert Opinion on Biological Therapy 2008, 8:337-349.
261. Webster A., Russell S., Talbot P., Russell W.C., Kemp G.D. Characterization of the adenovirus proteinase: Substrate specificity. The Journal of General Virology 1989, 70(Pt 12):3225-3234.
262. Wen X.Y., Mandelbaum S., Li Z.H., Hitt M., Graham F.L., Hawley T.S., et al. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma. Cancer Gene Therapy 2001, 8:361-370.
263. Wheeler M.D., Yamashina S., Froh M., Rusyn I., Thurman R.G. Adenoviral gene delivery can inactivate Kupffer cells: Role of oxidants in NF-kappaB activation and cytokine production. Journal of Leukocyte Biology 2001, 69:622-630.
264. Wickham T.J., Carrion M.E., Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Therapy 1995, 2:750-756.
265. Wickham T.J., Roelvink P.W., Brough D.E., Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature Biotechnology 1996, 14:1570-1573.
266. Wickham T.J., Segal D.M., Roelvink P.W., Carrion M.E., Lizonova A., Lee G.M., et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. Journal of Virology 1996, 70:6831-6838.
267. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacology & Therapeutics 1994, 64:529-564.
268. Wiethoff C.M., Wodrich H., Gerace L., Nemerow G.R. Adenovirus protein VI mediates membrane disruption following capsid disassembly. Journal of Virology 2005, 79:1992-2000.
269. Willimsky G., Blankenstein T. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors. Cancer Research 2000, 60:685-692.
270. Wirth T., Kuhnel F., Kubicka S. Telomerase-dependent gene therapy. Current Molecular Medicine 2005, 5:243-251.
271. Wold W.S.M., Horwitz M.S. Adenoviruses 2007, Lippincott-Raven, Philadelphia. 5th ed.
272. Wu H., Han T., Belousova N., Krasnykh V., Kashentseva E., Dmitriev I., et al. Identification of sites in adenovirus hexon for foreign peptide incorporation. Journal of Virology 2005, 79:3382-3390.
273. Wu E., Pache L., Von Seggern D.J., Mullen T.M., Mikyas Y., Stewart P.L., et al. Flexibility of the adenovirus fiber is required for efficient receptor interaction. Journal of Virology 2003, 77:7225-7235.
274. Xu Z., Tian J., Smith J.S., Byrnes A.P. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. Journal of Virology 2008, 82:11705-11713.
275. Yu W., Fang H. Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets 2007, 7:141-148.
276. Zaiss A.K., Liu Q., Bowen G.P., Wong N.C., Bartlett J.S., Muruve D.A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. Journal of Virology 2002, 76:4580-4590.
277. Zhan J., Gao Y., Wang W., Shen A., Aspelund A., Young M., et al. Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Therapy 2005, 12:19-25.
278. Zhang L., Akbulut H., Tang Y., Peng X., Pizzorno G., Sapi E., et al. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Molecular Therapy 2002, 6:386-393.
279. Zhang Y., Chirmule N., Gao G.P., Qian R., Croyle M., Joshi B., et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Molecular Therapy 2001, 3:697-707.
280. Zhang R., DeGroot L.J. Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12. Endocrinology 2003, 144:1393-1398.
281. Zhang X.Q., Dunner K., Benedict W.F. Autophagy is induced by adenoviral-mediated interferon alpha treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced. Cancer Gene Therapy 2010, 17:579-584.
282. Zhang J.F., Hu C., Geng Y., Selm J., Klein S.B., Orazi A., et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4513-4518.
283. Zhang F., Lu W., Dong Z. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clinical Cancer Research 2002, 8:2942-2951.
284. Zhang J.F., Wei F., Wang H.P., Li H.M., Qiu W., Ren P.K., et al. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. Journal of Experimental & Clinical Cancer Research 2010, 29:52.
285. Zheng S., Ulasov I.V., Han Y., Tyler M.A., Zhu Z.B., Lesniak M.S. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. The Journal of Gene Medicine 2007, 9:151-160.
286. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. Journal of Virology 2007, 81:3170-3180.